RxDoctor Payments Data

William Harris, MD

Geriatric Medicine · Charleston, WVNPI 1821162207

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $816 of the $996 with a category attached, or 81.9%. 9 manufacturers reported payments, led by GSK at 33.2% of the total. Reporting peaked in 2023 at $314 and has fallen 70.0% since, to $94 in 2025.

$996in general payments, 2019–2025

Across 62 payments — averaging $16.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$331
  • Lilly USA, LLC$241
  • Astellas Pharma US Inc$180
  • Bayer$88
  • Avanir Pharmaceuticals, Inc.$54
  • Novo Nordisk$34
  • plus $67 from 3 others

What the payments were for

  • Food & beverage$81682%
  • Education$18018%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few geriatric medicine providers in West Virginiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$274,376
Medicare patients
297
Services billed
9,959

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban182$255,057
MounjaroTirzepatide105$145,619
JanuviaSitagliptin Phosphate76$107,864
OzempicSemaglutide43$96,336
TradjentaLinagliptin49$63,252
XareltoRivaroxaban57$57,549
EntrestoSacubitril/Valsartan34$49,297
Tresiba Flextouch U-200Insulin Degludec21$47,409
JardianceEmpagliflozin25$40,121
MyrbetriqMirabegron29$36,893
Soliqua 100-33Insulin Glargine/Lixisenatide33$33,346
KerendiaFinerenone29$33,330
TrulicityDulaglutide18$33,088
RexultiBrexpiprazole11$28,138
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog30$27,453

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$241$178,706123 claims
Novo NordiskOzempic$34$96,33643 claims
Astellas Pharma US IncMyrbetriq$180$36,89329 claims
BayerKerendia$88$33,33029 claims
Otsuka America Pharmaceutical, Inc.Rexulti$26$28,13811 claims
GSKTrelegy Ellipta, Breo Ellipta$331$23,82537 claims
AbbVieSynthroid$29$10,14389 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few geriatric medicine providers in West Virginiaon file to place this against a meaningful peer group, so we don't.

Other geriatric medicine in Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →